Advertisement
Singapore markets close in 7 minutes
  • Straits Times Index

    3,327.22
    -2.87 (-0.09%)
     
  • Nikkei

    38,556.87
    -298.50 (-0.77%)
     
  • Hang Seng

    18,477.01
    -344.15 (-1.83%)
     
  • FTSE 100

    8,240.52
    -13.66 (-0.17%)
     
  • Bitcoin USD

    67,795.72
    -282.60 (-0.42%)
     
  • CMC Crypto 200

    1,460.78
    -23.92 (-1.61%)
     
  • S&P 500

    5,306.04
    +1.32 (+0.02%)
     
  • Dow

    38,852.86
    -216.74 (-0.55%)
     
  • Nasdaq

    17,019.88
    +99.08 (+0.59%)
     
  • Gold

    2,346.80
    -9.70 (-0.41%)
     
  • Crude Oil

    80.52
    +0.69 (+0.86%)
     
  • 10-Yr Bond

    4.5420
    +0.0750 (+1.68%)
     
  • FTSE Bursa Malaysia

    1,607.92
    -7.90 (-0.49%)
     
  • Jakarta Composite Index

    7,149.37
    -104.26 (-1.44%)
     
  • PSE Index

    6,411.41
    -89.93 (-1.38%)
     

Company News For May 13, 2024

  • Novavax, Inc. (NVAX) shares surged 98.7% after announcing a $1.2 billion deal with Sanofi (SNY) to commercialize a combined COVID-19 and flu vaccine.

  • Moderna, Inc. (MRNA) shares dropped 4.4% after the company announced that the Food and Drug Administration (FDA) postponed its approval decision for Moderna's respiratory syncytial virus (RSV) vaccine.

  • Shares of Genpact Limited (G) rose 3.6% after reporting first-quarter 2024 revenues of $1.13 billion, outpacing the Zacks Consensus Estimate of $1.11 billion.

  • IAMGOLD Corporation (IAG) shares increased 11.7% after reporting first-quarter 2024 adjusted earnings per share of $0.11, exceeding the Zacks Consensus Estimate of $0.2 per share.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Sanofi (SNY) : Free Stock Analysis Report

Moderna, Inc. (MRNA) : Free Stock Analysis Report

ADVERTISEMENT

Genpact Limited (G) : Free Stock Analysis Report

Novavax, Inc. (NVAX) : Free Stock Analysis Report

Iamgold Corporation (IAG) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research